PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
A phase 2 trial of Pembrolizumab in cervical cancer, run by Precigen, Inc, now recruiting.
Overview
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06157151 by Precigen, Inc, with 24 participants planned, started 2025-11-11 and due to reach its primary completion in 2026-11-11. Interventions recorded: PRGN-2009 plus Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Cervical cancer and the tag pipeline.
- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares Cervical cancer and the tag pipeline.
- TrialA Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Shares Cervical cancer and the tag pipeline.
- TrialAutologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Shares Pembrolizumab and the tag pipeline.
- TrialFirst in Human Study of T3P-Y058-739 (T3P)
Shares Pembrolizumab and the tag pipeline.
- TrialA Study of YL242 in Subjects With Advanced Solid Tumors
Shares Pembrolizumab and the tag pipeline.